![FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy - Merck.com FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy - Merck.com](https://s2.q4cdn.com/584635680/files/doc_events/2015/10/1/KEYTRUDA1.jpg)
FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy - Merck.com
![PDF] FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Semantic Scholar PDF] FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d87ced43628213babff1c81f9a45fcf02a22d940/2-Figure1-1.png)
PDF] FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Semantic Scholar
FDA Alerts Healthcare Professionals and Oncology Clinical Investigators about Two Clinical Trials on Hold Evaluating KEYTRUDA® (pembrolizumab) in Patients with Multiple Myeloma | FDA
![Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics | SpringerLink Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1208%2Fs12248-021-00574-0/MediaObjects/12248_2021_574_Fig1_HTML.png)
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics | SpringerLink
![FDA Grants Accelerated Approval to Pembrolizumab in Combination with Pemetrexed and Carboplatin for Treatment of Metastatic Non-Squamous NSCLC | ONS Voice FDA Grants Accelerated Approval to Pembrolizumab in Combination with Pemetrexed and Carboplatin for Treatment of Metastatic Non-Squamous NSCLC | ONS Voice](https://voice.ons.org//sites/default/files/FDA-Update-700.jpg)
FDA Grants Accelerated Approval to Pembrolizumab in Combination with Pemetrexed and Carboplatin for Treatment of Metastatic Non-Squamous NSCLC | ONS Voice
![Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Label Update to Treat Advanced Urothelial Carcinoma Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Label Update to Treat Advanced Urothelial Carcinoma](https://pharmashots.com/public/images/20211116015919_ogImage_8.jpg)
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Label Update to Treat Advanced Urothelial Carcinoma
![A reality check of the accelerated approval of immune-checkpoint inhibitors | Nature Reviews Clinical Oncology A reality check of the accelerated approval of immune-checkpoint inhibitors | Nature Reviews Clinical Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41571-019-0260-y/MediaObjects/41571_2019_260_Fig1_HTML.png)
A reality check of the accelerated approval of immune-checkpoint inhibitors | Nature Reviews Clinical Oncology
![FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Clinical Cancer Research FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Clinical Cancer Research](https://clincancerres.aacrjournals.org/content/clincanres/25/13/3753/F1.large.jpg?width=800&height=600&carousel=1)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Clinical Cancer Research
![Time line of FDA approvals for the anti-PD-1 antibodies pembrolizumab... | Download Scientific Diagram Time line of FDA approvals for the anti-PD-1 antibodies pembrolizumab... | Download Scientific Diagram](https://www.researchgate.net/publication/327840656/figure/fig2/AS:674379453181953@1537795999047/Time-line-of-FDA-approvals-for-the-anti-PD-1-antibodies-pembrolizumab-and-nivolumab.png)
Time line of FDA approvals for the anti-PD-1 antibodies pembrolizumab... | Download Scientific Diagram
![Approval of Keytruda in Europe for first-line use with chemotherapy in lung cancer strengthens the use of PD-1 inhibitors as backbone therapy, says GlobalData - GlobalData Approval of Keytruda in Europe for first-line use with chemotherapy in lung cancer strengthens the use of PD-1 inhibitors as backbone therapy, says GlobalData - GlobalData](https://eu.vocuspr.com/Publish/3434416/vcsPRAsset_3434416_86613_adfe21cc-289c-4282-baa5-a7e921161375_0.png)
Approval of Keytruda in Europe for first-line use with chemotherapy in lung cancer strengthens the use of PD-1 inhibitors as backbone therapy, says GlobalData - GlobalData
![FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis | Clinical Cancer Research FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis | Clinical Cancer Research](https://clincancerres.aacrjournals.org/content/clincanres/26/19/5062/F1.large.jpg?width=800&height=600&carousel=1)
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis | Clinical Cancer Research
![Pembrolizumab FDA approved for adjuvant treatment of melanoma – Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong Pembrolizumab FDA approved for adjuvant treatment of melanoma – Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong](https://cdn.medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982-495x400.jpg)
Pembrolizumab FDA approved for adjuvant treatment of melanoma – Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong
![Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic - Annals of Oncology Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a30a245e-c342-439c-85c1-d0d32df38ee8/gr2.jpg)